Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NXN 188

Next Previous
Drug Profile

NXN 188

Alternative Names: NXN-188

Latest Information Update: 08 Jun 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeurAxon
  • Class Small molecules
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Nitric oxide synthase inhibitors; Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 08 Jun 2015 Phase-II development of an oral formulation of NXN 188 is ongoing in the US, Canada and Denmark
  • 01 Jan 2015 NXN 188 licensed to Knight Therapeutics in Canada, Israel, South Africa and Russia
  • 31 Aug 2012 Preclinical study pharmacodynamics data in Migraine presented at the 14th World Congress on Pain (WCP-2012)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top